Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Invested Capital (2020 - 2025)

Xeris Biopharma Holdings' Invested Capital history spans 6 years, with the latest figure at $234.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital rose 15.57% year-over-year to $234.0 million, compared with a TTM value of $234.0 million through Dec 2025, up 15.57%, and an annual FY2025 reading of $234.0 million, up 15.57% over the prior year.
  • Invested Capital for Q4 2025 was $234.0 million at Xeris Biopharma Holdings, up from $218.6 million in the prior quarter.
  • The five-year high for Invested Capital was $234.1 million in Q1 2022, with the low at $19.9 million in Q2 2021.
  • Average Invested Capital over 5 years is $183.6 million, with a median of $200.6 million recorded in 2023.
  • Year-over-year, Invested Capital skyrocketed 966.02% in 2022 and then dropped 20.71% in 2023.
  • Tracing XERS's Invested Capital over 5 years: stood at $183.3 million in 2021, then increased by 26.71% to $232.3 million in 2022, then dropped by 20.71% to $184.2 million in 2023, then grew by 9.96% to $202.5 million in 2024, then rose by 15.57% to $234.0 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Invested Capital are $234.0 million (Q4 2025), $218.6 million (Q3 2025), and $199.3 million (Q2 2025).